PA8.F stock drops 30.86% after hours on 19 Feb 2026: watch cash runway

PA8.F stock plunged 30.86% in after-hours trading on 19 Feb 2026 to EUR 0.093 on XETRA (Germany), signaling one of the session’s largest losers. Trading volume remained light at 400 shares and market cap sits at EUR 870311, reflecting a very small-cap structure. Investors should note the one-day gap from the previous close of EUR 0.1345, an unusually sharp move for a Healthcare small cap in the Drug Manufacturers – Specialty & Generic industry.

PA8.F stock: after-hours price action and key market facts

Paion AG (PA8.F) closed the regular session and moved lower in after hours to EUR 0.093, down EUR 0.0415 or 30.86% versus the prior close of EUR 0.1345. The day range was tight with both the day low and day high at EUR 0.093, and traded volume was 400 versus a 50-day average volume of 2,162.

This move places PA8.F well above the 50-day average price (EUR 0.022) and the 200-day average price (EUR 0.015), but the stock remains volatile; year high is EUR 0.180 and year low is effectively near EUR 0.000, underscoring prior extreme range compression and low liquidity on XETRA.

Valuation and financial metrics for PA8.F stock

On headline metrics Paion shows a market cap of EUR 870311 with 7,133,700 shares outstanding. Price-to-sales (TTM) is 0.03 and reported PE (TTM) reads roughly -1.50, reflecting negative net income per share of -0.081. Revenue per share (TTM) is 4.66, while gross margin sits at 94.10%, indicating high product-level margins but limited scale.

Operating metrics show elevated SG&A at 63.76% of revenue and R&D at 19.50% of revenue. Cash and liquidity line items are thin on public data; interest coverage is low at 0.54, which increases sensitivity to financing events and news-driven swings in the PA8.F stock price.

Technical picture and trading signals for PA8.F stock

Momentum indicators are mixed: RSI is 57.45 and MACD sits at 0.03 with neutral histogram, while ADX at 53.24 points to a strong trend. Bollinger Bands show a middle band near EUR 0.110 and an upper band near EUR 0.230, implying elevated implied volatility despite low liquidity.

Volume-based indicators show on-balance volume accumulation but absolute volumes remain low. Given the ATR of EUR 0.030, intraday swings of this magnitude are possible; traders should expect wide spreads and potential execution risk when trading PA8.F stock on XETRA.

Meyka grade and model forecast for PA8.F stock

Meyka AI rates PA8.F with a score out of 100: 62.88 / Grade B / Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector and industry performance, financial growth, key metrics, forecasts, analyst consensus, and fundamental growth. These grades are informational only and not financial advice.

Meyka AI’s forecast model projects a monthly target of EUR 0.34 and a quarterly target of EUR 0.06. Compared with the current price of EUR 0.093, the monthly projection implies an upside of 265.60%, while the quarterly projection implies a downside of -35.48%. Forecasts are model-based projections and not guarantees.

Catalysts, calendar events and sector context for PA8.F stock

Upcoming items that could move PA8.F include the company’s scheduled earnings announcement on 2026-04-02 and any operational updates on sedative product commercialization or licensing deals. The Healthcare sector in Germany has been modestly positive YTD, but small specialty drug makers face binary outcomes from trial and licensing news.

Paion operates in Drug Manufacturers – Specialty & Generic, where peers’ performance and M&A chatter can sway sentiment quickly. Investors should monitor company releases and sector developments, and consult Paion’s site for primary filings: Paion AG website.

Risks, trading strategy and practical considerations for PA8.F stock

Main risks include low liquidity, limited public financial detail, sensitivity to clinical or licensing updates, and thin cash reserves implied by low market cap. A sharp after-hours move like today increases execution risk for larger orders and widens bid-ask spreads on XETRA.

For traders, consider limit orders and tight position sizing. For longer-term investors, require clarity on cash runway, upcoming earnings, and a defined catalyst. Check the Paion profile image and data source for reference: FinancialModelingPrep profile image. Internal Meyka coverage is available at our PA8.F page for live updates.

Final Thoughts

PA8.F stock registered a steep after-hours decline to EUR 0.093 on 19 Feb 2026, down 30.86%, highlighting the stock’s small-cap volatility and low liquidity on XETRA in Germany. Key fundamentals show very low market cap (EUR 870311), negative net income per share (-0.081), a price-to-sales ratio of 0.03, and modest operating margins. Meyka AI rates PA8.F 62.88 / B / HOLD and flags both upside and downside in its model. Specifically, Meyka AI’s forecast model projects EUR 0.34 monthly (implied upside 265.60%) and EUR 0.06 quarterly (implied downside -35.48%). These divergent targets reflect model sensitivity to short-term news versus longer momentum. Investors should treat PA8.F as a high‑volatility, speculative exposure and prioritise confirmation of cash runway and the 2026-04-02 earnings update before increasing position size. Meyka AI provides this as an AI-powered market analysis platform insight, not investment advice; perform your own due diligence and manage risk carefully.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.